Delgocitinib cream had superior efficacy and a better safety profile compared with oral alitretinoin for the treatment of ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 LEO Pharma A/S, a global leader in ...

More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with moderate to severe chronic hand eczema ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

This is the second of two phase 3 delgocitinib cream trials to achieve ... global research & development, LEO Pharma. "It is incredibly exciting to see the level of consistency that our DELTA ...

Delgocitinib cream is efficacious and well-tolerated for the treatment of adults with chronic hand eczema for up to 52 weeks.

Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.

Treatment with delgocitinib cream ... This trial was sponsored by LEO Pharma A/S. Four authors reported being employees of LEO Pharma A/S. Several authors reported being speaker or advisor ...

“The discussion of delgocitinib and the presentation of DELTA FORCE data in The Lancet is an exciting moment for the LEO Pharma team,” said Robert Spurr, EVP, LEO Pharma, North America and ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 ...